StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 7.9 %
Shares of TTNP stock opened at $3.96 on Thursday. The company has a fifty day moving average price of $5.57 and a two-hundred day moving average price of $6.05. Titan Pharmaceuticals has a one year low of $3.96 and a one year high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 10 Best Airline Stocks to Buy
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- 3 Warren Buffett Stocks to Buy Now
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
